Trial reportAntimicrobial agents and chemotherapy2023
A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.
Open access · hybridAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
In one paragraph
Trial report in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Meta-analysis of Randomized controlled trials.BMC infectious diseases · 2024Pooled it
- One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Discovery of Highly Selective Noncovalent Macrocyclic Peptide Inhibitors Suppressing Both TMPRSS2 Protease Activity and Viral Receptor Function.Journal of medicinal chemistry · 2026Article
- Epistasis and co-adaptation in bacterial genome evolution.Nature reviews. Genetics · 2026Review
- Lock out: targeting TMPRSS2 to block influenza and coronaviruses.Journal of virology · 2026Review
- Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas.ChemMedChem · 2026Article
- Individual patient data meta-analysis and systematic review evaluating camostat mesilate to treat COVID-19.Journal of clinical and translational science · 2026Article
- Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants.Journal of medicinal chemistry · 2025Article
- Antivirals in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.Expert opinion on drug discovery · 2024Review
- An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.International journal of molecular sciences · 2023Review
- Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study.Pharmaceutics · 2023Article
- SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.Journal of virology · 2023Article
- Aprotinin-Drug against Respiratory Diseases.International journal of molecular sciences · 2023Review
- Therapeutic developments for SARS-CoV-2 infection-Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 12 institutions in 1 country.
Yeon-Sook KimDepartment of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea.
Seng-Ho JeonDaewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
Junghee KimDepartment of Neurosurgery, Seoul Medical Center, Seoul, South Korea.
Jong Hoon KohDepartment of Internal Medicine, Seonam Hospital, Seoul, South Korea.
Seung Won RaDepartment of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
Ji Won KimDepartment of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.
Yeonjae KimDivision of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul, South Korea.
Choon Kwan KimDepartment of Internal Medicine, Veterans Health Service Medical Center, Seoul, South Korea.
Yun Chul ShinDepartment of Anesthesiology and Pain Medicine, Gyeonggi Provincial Medical Center Pocheon Hospital, Pocheon, South Korea.
Beo Deul KangDepartment of Internal Medicine, Gyeonggi Provincial Medical Center Ansung Hospital, Ansung, South Korea.
Seung Ji KangDepartment of Internal Medicine, Chonmam National University Medical School, Gwangju, South Korea.
Chul Hee ParkDepartment of Internal Medicine, Gyeonggi Provincial Medical Center Icheon Hospital, Icheon, South Korea.
Boyoung LeeDepartment of Internal Medicine, Gyeonggi Provincial Medical Center Uljeongbu Hospital, Uljeongbu, South Korea.
Ji Yeon LeeDepartment of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, South Korea.
Chung Hoon LeeDepartment of Obstetrics and Gynecology, Gyeonggi Provincial Medical Center Suwon Hospital, Suwon, South Korea.
Jae-Phil ChoiDepartment of Internal Medicine, Seoul Medical Center, Seoul, South Korea.
Jin Yong KimDepartment of Internal Medicine, Incheon Medical Center, Incheon, South Korea.
Shi Nae YuDepartment of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea.
Kyong Ran PeckDivision of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Sung-Han KimDepartment of Internal Medicine, Asan Medical Centergrid.413967.e, Seoul, South Korea.
Jung Yeon HeoDepartment of Infectious Diseases, Ajou University School of Medicine, Suwon, South Korea.
Hyun Ah KimDepartment of Medicine, Division of Infectious Diseases, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
Hyun-Jin ParkClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
Jongwon ChoiClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
Jumi HanClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
JooHyun KimClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
Hyoung Jun KimClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
Se Hee HanClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
Aeri YoonClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
MiHee ParkClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
SuJung ParkClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
YuKyung KimClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.
Minji JungClinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea.ORCID 0000-0001-8533-7873
Myoung-Don OhDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0002-2344-7695
Daewoong Pharmaceutical (South Korea) · KRSeoul National University · KRChungnam National University · KRChonnam National University · KRGyeongsang National University Hospital · KRSeoul Medical Center · KRSoonchunhyang University · KRSuwon Research Institute · KRUlsan College · KRAsan Medical Center · KRIncheon Medical Center · KRSamsung Medical Center · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although several antiviral agents have become available for coronavirus disease 2019 (COVID-19) treatment, oral drugs are still limited. Camostat mesylate, an orally bioavailable serine protease inhibitor, has been used to treat chronic pancreatitis in South Korea, and it has an
Indexed as
COVID-19AdultDouble-Blind MethodEstersGuanidinesHumansSARS-CoV-2Treatment OutcomecamostatEstersGuanidinesantiviral agentcamostat mesylateclinical trialcoronavirus disease 2019SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.